Inada H, Kurano S, Miyamoto H, Onishi M, et al. TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma. J Gastroenterol 2025 Nov 17. doi: 10.1007/s00535-025-02320.
PMID: 41247518